2025
Mepolizumab in patients with severe asthma & BEC ≥150–<300 cells/µL: Benefits at 2 years
Canonica G, Bagnasco D, Lee J, Chupp G, Schleich F, Oppenheimer J, Zhang L, Alfonso-Cristancho R, Howarth P. Mepolizumab in patients with severe asthma & BEC ≥150–<300 cells/µL: Benefits at 2 years. ERJ Open Research 2025, 01390-2024. DOI: 10.1183/23120541.01390-2024.Peer-Reviewed Original ResearchClinically significant exacerbationsBlood eosinophil countMaintenance oral corticosteroidsSevere asthmaRate of clinically significant exacerbationsMedian average daily doseFEV 1Effect of mepolizumabInitiation of mepolizumabProportion of patientsObservational cohort studyReal-world effectivenessClinical trial evidenceForced expiratory volumePoor disease controlMepolizumab treatmentAverage daily doseOral corticosteroidsSingle-armACQ-5Daily doseSignificant exacerbationsEosinophil countMepolizumabCohort study
2024
Activated sputum eosinophils associated with exacerbations in children on mepolizumab
Wilson G, Knight J, Liu Q, Shelar A, Stewart E, Wang X, Yan X, Sanders J, Visness C, Gill M, Gruchalla R, Liu A, Kattan M, Khurana Hershey G, Togias A, Becker P, Altman M, Busse W, Jackson D, Montgomery R, Chupp G. Activated sputum eosinophils associated with exacerbations in children on mepolizumab. Journal Of Allergy And Clinical Immunology 2024, 154: 297-307.e13. PMID: 38485057, PMCID: PMC11305967, DOI: 10.1016/j.jaci.2024.01.031.Peer-Reviewed Original ResearchAirway eosinophilsSputum eosinophilsPatients treated with mepolizumabPlacebo-controlled clinical trialAnti-IL-5 treatmentEffect of mepolizumabEosinophil subpopulationsSevere eosinophilic asthmaAnti-interleukin-5Expression of CD62LFrequency of exacerbationsEosinophilic asthmaActivation markersSputum samplesUnsupervised cluster analysisMepolizumabTreatment armsReduce exacerbationsCD62LClinical trialsExacerbationMass cytometryEosinophilsExacerbation riskIntracellular markers
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply